+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Human Microbiome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product, Disease, Application, and Geography

  • ID: 4756874
  • Report
  • September 2020
  • Region: Global
  • 207 pages
  • The Insight Partners
UP TO OFF
until Jan 31st 2021

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AOBiome LLC
  • DuPont
  • Enterome
  • MaaT Pharma
  • Osel Inc.
  • Seres Therapeutics
Prebiotics Segment to Grow at Highest CAGR during 2020-2027

According to this new market research study on “Human Microbiome Market to 2027 - COVID-19 Impact and Global Analysis - by Product, Disease, Application, and Geography,” the market is expected to reach US$ 4,542.67 million by 2027 from US$ 2,620.88 million in 2019. Increasing focus on human microbiome therapies and growing technological advancements in metagenomics and next-generation sequencing are expected to boost the growth of the market. On the other hand, strict government guidelines and lack of knowledge about detailed examination are likely to have a negative impact on the growth of the market in the coming years.

Based on product, the human microbiome market is segmented into probiotics, foods, prebiotics, medical foods, diagnostic devices, drugs, and supplements. In 2019, the probiotics segment held the largest share of the human microbiome market. This segment is expected to dominate the market in 2027 owing to increasing health concerns; growing awareness regarding the relation of nutrition, diet, and health; and increasing probiotics market penetration in dairy and other foods. Furthermore, the prebiotics segment is anticipated to witness the fastest growth rate during the forecast period.

Fecal microbiota transplantation (FMT) has emerged as an effective treatment for C. difficile infection (CDI). The microbiota have important roles in the function of gastrointestinal tract and other aspects of human physiology. There has been rise in interest in studying FMT for other clinical indications. The US Food and Drug Administration (FDA) has classified human stool as a biological agent and determined that the use of human stool in FMT therapy and other research must be regulated for the insurance of patient safety. To use FMT in the treatment of recurrent Clostridium difficile infection, an investigational new drug permit is not required, but it is strongly encouraged and may ultimately be required. In March 2016, the US FDA released clarifying guidance and the draft of Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements that focused on the use of Fecal Microbiota for Transplantation to Treat Clostridium difficile infection when the patients is not responsive to standard therapies. Some of the available data suggests that the use of fecal microbiota for the restoration of intestinal flora may be an effective therapy in the management of refractory C. difficile infection. However, the efficiency and protection profiles of this intervention have not yet been fully evaluated in controlled clinical trials. Thus, the investigational drug requirement plays a vital role in the application of microbiome, thereby giving it an array of opportunities in future.

Several players have observed good demand for human microbiome based products during the initial period of COVID-19, particularly from the food & beverages industry. In addition, researchers are studying the correlation between gut bacteria and COVID-19. Many researchers have showcased gut bacteria's implication in different health conditions, from type 2 diabetes to depression. However, the obstacles in supply chains and distribution networks resulting in unavailability of human microbiome based products in various parts of the world are likely to hamper the growth of the market in 2020.

Enterome; Rebiotix Inc.; Yakult Honsha Co., Ltd.; Osel Inc.; Vedanta Biosciences, Inc.; Synthetic Biologics, Inc.; DuPont; BiomX Ltd; MaaT Pharma; Eligo Bioscience; Merck & Co., Inc.; AOBiome LLC; Kaleido; and Seres Therapeutics are among the leading companies operating in the human microbiome market.

The report segments the global human microbiome market as follows:

By Product
  • Probiotics
  • Foods
  • Prebiotics
  • Medical Foods
  • Diagnostic Device
  • Drugs
  • Supplements
By Disease
  • Obesity
  • Diabetes
  • Autoimmune Disorders
  • Cancer
  • Mental Disorders
  • Others
By Application
  • Therapeutics
  • Diagnostics
By Geography

North America
  • US
  • Canada
  • Mexico
Europe
  • France
  • Germany
  • UK
  • Spain
  • Italy
Asia Pacific (APAC)
  • China
  • India
  • Japan
  • Australia
  • South Korea
Middle East & Africa (MEA)
  • Saudi Arabia
  • UAE
  • South Africa
  • South and Central America (SCAM)
  • Brazil
  • Argentina
Reasons to Buy
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the human microbiome market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AOBiome LLC
  • DuPont
  • Enterome
  • MaaT Pharma
  • Osel Inc.
  • Seres Therapeutics
1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Global Human Microbiome Market - By Product
1.3.2 Global Human Microbiome Market - by Disease
1.3.3 Global Human Microbiome Market - by Application
1.3.4 Global Human Microbiome Market - By Geography

2. Human Microbiome Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Global Human Microbiome Market - Market Landscape
4.1 Overview
4.1.1 North America - PEST Analysis
4.1.2 Europe- PEST Analysis
4.1.3 Asia Pacific- PEST Analysis
4.1.4 Middle East And Africa- PEST Analysis
4.1.5 South and Central America - PEST Analysis
4.2 Expert Opinions

5. Human Microbiome Market- Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Increasing Incidence of Lifestyle Diseases
5.1.2 Increasing Focus On Human Microbiome Therapies
5.1.3 Growing Technological Advancements in Metagenomics and Next-generation Sequencing
5.2 Key Market Restraints
5.2.1 Strict Government Guidelines
5.2.2 Lack of Knowledge and Detailed Examination
5.3 Key Market Opportunities
5.3.1 New Drug Requirements for Faecal Microbiota
5.3.2 Emerging Nations
5.4 Future Trends
5.4.1 The Human Microbiome - A New Frontier in Drug Discovery
5.5 Impact analysis

6. Human Microbiome Market - Global Analysis
6.1 Global Human Microbiome Market Revenue Forecast and Analysis
6.2 Global Human Microbiome Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players

7. Human Microbiome Market Analysis - By Product
7.1 Overview
7.2 Human Microbiome Market Revenue Share, by Product (2019 and 2027)
7.3 Foods
7.3.1 Overview
7.3.2 Foods: Human Microbiome Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Medical Food
7.4.1 Overview
7.4.2 Medical Food: Human Microbiome Market - Revenue and Forecast to 2027 (US$ Million)
7.5 Probiotics
7.5.1 Overview
7.5.2 Probiotics: Human Microbiome Market - Revenue and Forecast to 2027 (US$ Million)
7.6 Drugs
7.6.1 Overview
7.6.2 Drugs: Human Microbiome Market - Revenue and Forecast to 2027 (US$ Million)
7.7 Diagnostic Devices
7.7.1 Overview
7.7.2 Diagnostic Devices: Human Microbiome Market - Revenue and Forecast to 2027 (US$ Million)
7.8 Supplements
7.8.1 Overview
7.8.2 Supplements: Human Microbiome Market - Revenue and Forecast to 2027 (US$ Million)

8. Human Microbiome Market Analysis - By Disease
8.1 Overview
8.2 Human Microbiome Market Revenue Share, by Disease(2019 and 2027)
8.3 Diabetes
8.3.1 Overview
8.3.2 Global Diabetes Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Cancer
8.4.1 Overview
8.4.2 Global Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Autoimmune Disorders
8.5.1 Overview
8.5.2 Global Autoimmune Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Obesity
8.6.1 Overview
8.6.2 Global Obesity Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Mental Disorders
8.7.1 Overview
8.7.2 Global Mental Disorders Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Others Market
8.8.1 Overview
8.8.2 Global Others Market Revenue and Forecasts to 2027 (US$ Mn)

9. Human Microbiome Market Analysis - By Application
9.1 Overview
9.2 Human Microbiome Market Revenue Share, by Application(2019 and 2027)
9.3 Diagnostics
9.3.1 Overview
9.3.2 Diagnostics:Human Microbiome Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Therapeutics
9.4.1 Overview
9.4.2 Therapeutics:Human Microbiome Market - Revenue and Forecast to 2027 (US$ Million)

10. Human Microbiome Market Analysis and Forecasts To 2027 Geographical Analysis
10.1 North America: Human Microbiome Market
10.1.1 Overview
10.1.2 North America: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.1.3 North America: Human Microbiome Market, by Product, 2018-2027 (USD Million)
10.1.4 North America: Human Microbiome Market, by Disease, 2018-2027 (USD Million)
10.1.5 North America: Human Microbiome Market, by Application, 2018-2027 (USD Million)
10.1.6 North America: Human Microbiome Market, by Country, 2019 & 2027 (%)
10.1.7 US: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.1.7.1 US: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.1.7.2 US: Human Microbiome Market, by Product, 2018-2027 (USD Million)
10.1.7.3 US: Human Microbiome Market, by Disease, 2018-2027 (USD Million)
10.1.7.4 US: Human Microbiome Market, by Application, 2018-2027 (USD Million)
10.1.8 Canada: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.1.8.1 Canada: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.1.8.2 Canada: Human Microbiome Market, by Product, 2018-2027 (USD Million)
10.1.8.3 Canada: Human Microbiome Market, by Disease, 2018-2027 (USD Million)
10.1.8.4 Canada: Human Microbiome Market, by Application, 2018-2027 (USD Million)
10.1.9 Mexico: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.1.9.1 Mexico: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.1.9.2 Mexico: Human Microbiome Market, by Product, 2018-2027 (USD Million)
10.1.9.3 Mexico: Human Microbiome Market, by Disease, 2018-2027 (USD Million)
10.1.9.4 Mexico: Human Microbiome Market, by Application, 2018-2027 (USD Million)
10.2 Europe: Human Microbiome Market
10.2.1 Overview
10.2.2 Europe: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.3 Europe Human Microbiome Market, by Product - Revenue and Forecast to 2027 (USD Million)
10.2.4 Europe Human Microbiome Market, by Disease - Revenue and Forecast to 2027 (USD Million)
10.2.5 Europe Human Microbiome Market, by Application - Revenue and Forecast to 2027 (USD Million)
10.2.6 Europe: Human Microbiome Market, by Country, 2019 & 2027 (%)
10.2.7 Germany: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.7.1 Germany: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.7.2 Germany Human Microbiome Market, by Product - Revenue and Forecast to 2027 (USD Million)
10.2.7.3 Germany Human Microbiome Market, by Disease - Revenue and Forecast to 2027 (USD Million)
10.2.7.4 Germany Human Microbiome Market, by Application- Revenue and Forecast to 2027 (USD Million)
10.2.8 UK: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.8.1 UK: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.8.2 UK Human Microbiome Market, by Product - Revenue and Forecast to 2027 (USD Million)
10.2.8.3 UKHuman Microbiome Market, by Disease- Revenue and Forecast to 2027 (USD Million)
10.2.8.4 UK: Human Microbiome Market, Usability - Revenue and Forecast to 2027 (USD Million)
10.2.9 France: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.9.1 France: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.9.2 France Human Microbiome Market, by Product - Revenue and Forecast to 2027 (USD Million)
10.2.9.3 France Human Microbiome Market, by Disease - Revenue and Forecast to 2027 (USD Million)
10.2.9.4 France Human Microbiome Market, by Application - Revenue and Forecast to 2027 (USD Million)
10.2.10 Spain: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.10.1 Spain: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.10.2 Spain Human Microbiome Market, by Product - Revenue and Forecast to 2027 (USD Million)
10.2.10.3 Spain Human Microbiome Market, by Disease- Revenue and Forecast to 2027 (USD Million)
10.2.10.4 Spain Human Microbiome Market, by Application- Revenue and Forecast to 2027 (USD Million)
10.2.11 Italy: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.11.1 Italy: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.2.11.2 Italy Human Microbiome Market, by Product - Revenue and Forecast to 2027 (USD Million)
10.2.11.3 Italy Human Microbiome Market, by Disease - Revenue and Forecast to 2027 (USD Million)
10.2.11.4 Italy Human Microbiome Market, by Application - Revenue and Forecast to 2027 (USD Million)
10.3 Asia Pacific: Human Microbiome Market
10.3.1 Overview
10.3.2 Asia Pacific: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.3 Asia Pacific: Human Microbiome Market, by Product, 2018-2027 (USD Million)
10.3.4 Asia Pacific: Human Microbiome Market, by Disease, 2018-2027 (USD Million)
10.3.5 Asia Pacific: Human Microbiome Market, by Application, 2018-2027 (USD Million)
10.3.6 Asia Pacific: Human Microbiome Market, by Country, 2018 & 2027 (%)
10.3.7 China: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.7.1 China: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.7.2 China: Human Microbiome Market, by Product, 2018-2027 (USD Million)
10.3.7.3 ChinaHuman Microbiome Market, by Disease, 2018-2027 (USD Million)
10.3.7.4 China Human Microbiome Market, by Application, 2018-2027 (USD Million)
10.3.8 Japan: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.8.1 Japan: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.8.2 Japan: Human Microbiome Market, by Product, 2018-2027 (USD Million)
10.3.8.3 JapanHuman Microbiome Market, by Disease, 2018-2027 (USD Million)
10.3.8.4 JapanHuman Microbiome Market, by Application, 2018-2027 (USD Million)
10.3.9 India: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.9.1 India: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.9.2 India: Human Microbiome Market, by Product, 2018-2027 (USD Million)
10.3.9.3 IndiaHuman Microbiome Market, by Disease, 2018-2027 (USD Million)
10.3.9.4 IndiaHuman Microbiome Market, by Application, 2018-2027 (USD Million)
10.3.10 South Korea: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.10.1 South Korea: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.10.2 South Korea: Human Microbiome Market, by Product, 2018-2027 (USD Million)
10.3.10.3 South KoreaHuman Microbiome Market, by Disease, 2018-2027 (USD Million)
10.3.10.4 South KoreaHuman Microbiome Market, by Application, 2018-2027 (USD Million)
10.3.11 Australia: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.11.1 Australia: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.3.11.3 Australia: Human Microbiome Market, by Product, 2018-2027 (USD Million)
10.3.11.4 Australia Human Microbiome Market, by Disease, 2018-2027 (USD Million)
10.3.11.5 Australia Human Microbiome Market, by Application, 2018-2027 (USD Million)
10.4 Middle East & Africa: Human Microbiome Market
10.4.1 Overview
10.4.2 Middle East & Africa: Human Microbiome Market - Revenue and Forecast to 2027 (US$ Million)
10.4.3 Middle East & Africa Human Microbiome Market, by Product- Revenue and Forecast to 2027 (USD Million)
10.4.4 Middle East & Africa Human Microbiome Market, by Disease- Revenue and Forecast to 2027 (USD Million)
10.4.5 Middle East & Africa Human Microbiome Market, by Application- Revenue and Forecast to 2027(USD Million)
10.4.6 Middle East & Africa: Human Microbiome Market, by Country, 2019& 2027 (%)
10.4.6.1 Saudi Arabia: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.4.6.2 Saudi Arabia: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.4.6.3 Saudi Arabia Human Microbiome Market, by Product- Revenue and Forecast to 2027 (USD Million)
10.4.6.4 Saudi Arabia Human Microbiome Market, by Disease- Revenue and Forecast to 2027 (USD Million)
10.4.6.5 Saudi Arabia Human Microbiome Market, by Application- Revenue and Forecast to 2027(USD Million)
10.4.7 UAE: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.4.7.1 UAE: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.4.7.2 UAE Human Microbiome Market, by Product- Revenue and Forecast to 2027 (USD Million)
10.4.7.3 UAE Human Microbiome Market, by Disease- Revenue and Forecast to 2027 (USD Million)
10.4.7.4 UAE Human Microbiome Market, by Application- Revenue and Forecast to 2027(USD Million)
10.4.8 South Africa: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.4.8.1 South Africa: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.4.8.2 South Africa Human Microbiome Market, by Product- Revenue and Forecast to 2027 (USD Million)
10.4.8.3 South Africa Human Microbiome Market, by Disease- Revenue and Forecast to 2027 (USD Million)
10.4.8.4 South Africa Human Microbiome Market, by Application- Revenue and Forecast to 2027(USD Million)
10.5 South and Central America: Human Microbiome Market
10.5.1 Overview
10.5.2 South and Central America: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.5.3 South and Central America Human Microbiome Market, by Product- Revenue and Forecast to 2027 (USD Million)
10.5.4 South and Central America Human Microbiome Market, by Disease- Revenue and Forecast to 2027 (USD Million)
10.5.5 South and Central America Human Microbiome Market, by Application- Revenue and Forecast to 2027 (USD Million)
10.5.6 South and Central America: Human Microbiome Market, by Country, 2019 & 2027 (%)
10.5.7 Brazil: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.5.7.1 Brazil: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.5.7.2 Brazil Human Microbiome Market, by Product- Revenue and Forecast to 2027 (USD Million)
10.5.7.3 Brazil Human Microbiome Market, by Disease- Revenue and Forecast to 2027 (USD Million)
10.5.7.4 Brazil Human Microbiome Market, by Application- Revenue and Forecast to 2027(USD Million)
10.5.8 Argentina: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.5.8.1 Argentina: Human Microbiome Market - Revenue and Forecast to 2027 (USD Million)
10.5.8.2 Argentina Human Microbiome Market, by Product- Revenue and Forecast to 2027 (USD Million)
10.5.8.3 Argentina Human Microbiome Market, by Disease- Revenue and Forecast to 2027 (USD Million)
10.5.8.4 Argentina Human Microbiome Market, by Application- Revenue and Forecast to 2027(USD Million)

11. Impact of COVID-19 Pandemic on Global Human Microbiome Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Human Microbiome Market - Industry Landscape
12.1 Growth Strategies in the Human Microbiome Market, 2015-2020
12.2 Organic Growth Strategies
12.2.1 Overview
12.2.2 Product Launch & Approvals
12.2.3 Expansion
12.2.4 Patent and license
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.3.2 Acquisitions
12.3.3 Partnerships, Collaborations & Agreements
12.3.4 Joint Ventures

13. Company Profiles
13.1 ENTEROME
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Financial Overview
13.1.4 Product Portfolio
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Rebiotix Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Financial Overview
13.2.4 Product Portfolio
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Yakult Honsha Co., Ltd.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Financial Overview
13.3.4 Product Portfolio
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Osel Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Financial Overview
13.4.4 Product Portfolio
13.4.5 Swot Analysis
13.4.6 Key Developments
13.5 Vedanta Biosciences, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Financial Information
13.5.4 Product Portfolio
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Synthetic Biologics, Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Financial Information
13.6.4 Product Portfolio
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 DuPont
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Financial Overview
13.7.4 Product Portfolio
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 BiomX
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Financial Information
13.8.4 Product Portfolio
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 MaaT Pharma
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 ELIGO BIOSCIENCE
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 AOBiome
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 Kaleido Biosciences, Inc.
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
13.13 Seres Therapeutics
13.13.1 Key Facts
13.13.2 Business Description
13.13.3 Products and Services
13.13.4 Financial Overview
13.13.5 SWOT Analysis
13.13.6 Key Developments
13.14 Merck & Co., Inc.
13.14.1 Key Facts
13.14.2 Business Description
13.14.3 Products and Services
13.14.4 Financial Overview
13.14.5 SWOT Analysis
13.14.6 Key Developments

14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Enterome
  • Rebiotix Inc.
  • Yakult Honsha Co., Ltd.
  • Osel Inc.
  • Vedanta Biosciences, Inc.
  • Synthetic Biologics, Inc.
  • DuPont
  • BiomX Ltd
  • MaaT Pharma
  • Eligo Bioscience
  • Merck & Co., Inc
  • AOBiome LLC
  • Kaleido
  • Seres Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll